1
|
Kakinuma R, Ashizawa K, Kobayashi T, Fukushima A, Hayashi H, Kondo T, Machida M, Matsusako M, Minami K, Oikado K, Okuda M, Takamatsu S, Sugawara M, Gomi S, Muramatsu Y, Hanai K, Muramatsu Y, Kaneko M, Tsuchiya R, Moriyama N. Comparison of sensitivity of lung nodule detection between radiologists and technologists on low-dose CT lung cancer screening images. Br J Radiol 2012; 85:e603-8. [PMID: 22919013 DOI: 10.1259/bjr/75768386] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
OBJECTIVES The objective of this study was to compare the sensitivity of detection of lung nodules on low-dose screening CT images between radiologists and technologists. METHODS 11 radiologists and 10 technologists read the low-dose screening CT images of 78 subjects. On images with a slice thickness of 5 mm, there were 60 lung nodules that were ≥5 mm in diameter: 26 nodules with pure ground-glass opacity (GGO), 7 nodules with mixed ground-glass opacity (GGO with a solid component) and 27 solid nodules. On images with a slice thickness of 2 mm, 69 lung nodules were ≥5 mm in diameter: 35 pure GGOs, 7 mixed GGOs and 27 solid nodules. The 21 observers read screening CT images of 5-mm slice thickness at first; then, 6 months later, they read screening CT images of 2-mm slice thickness from the 78 subjects. RESULTS The differences in the mean sensitivities of detection of the pure GGOs, mixed GGOs and solid nodules between radiologists and technologists were not statistically significant, except for the case of solid nodules; the p-values of the differences for pure GGOs, mixed GGOs and solid nodules on the CT images with 5-mm slice thickness were 0.095, 0.461 and 0.005, respectively, and the corresponding p-values on CT images of 2-mm slice thickness were 0.971, 0.722 and 0.0037, respectively. CONCLUSION Well-trained technologists may contribute to the detection of pure and mixed GGOs ≥5 mm in diameter on low-dose screening CT images.
Collapse
Affiliation(s)
- R Kakinuma
- Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N. What we know from the semiannually repeated CT screening in a high-risk cohort over 15 years: Update of Anti-Lung Cancer Association project. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N. What size tumors should we detect as early-stage lung cancers in CT screening? Stage-size relationship in long-term repeated screening over 15 years. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N. Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1540 Background: We have investigated the individualized benefit of CT screening as Anti-Lung Cancer Association projects (presented at ASCO 2006–2008). However, there has not been enough information about the relationship of lung cancer stage to tumor size in repeated CT screening. Therefore, we evaluated the stage-size relationship of these asymptomatic lung cancer cases diagnosed by long-term repeated screening with low-dose helical CT. Methods: Among 2,120 participants (mean age 63 years, 87% male, and 83% smoker) at baseline screening, 1,877 underwent semiannually repeated screening from 1993 to 2004. Nineteen (0.90%) prevalence cancers and 57 (0.32%) incidence cancers were detected. Within categories of tumor size, the distribution of pathological stage, histology, lymph node status, and distant metastases was determined. Results: Pathological stage has a strong relationship to tumor size at baseline screening (spearman r = 0.63, p = 0.013) and repeated screening (r = 0.65, p < 0.001). In the analysis of all 76 cases, lymph node status (r = 0.59, p < 0.001) and distant metastases (r = 0.55, p = 0.005) have also a strong relationship to tumor size. The percentages of cases with no metastases (N0M0) were 100% (0/21), 89% (17/19), 62% (8/13), 83% (10/12), 50% (4/8), and 33% (1/3) for the categories 10 mm or less, 11 mm to 15 mm, 16 mm to 20 mm, 21 mm to 30 mm, 31 mm to 40 mm, and 41 mm or greater, respectively. Histology for the categories 15 mm or less was localized bronchioloalveolar carcinoma in 13 cases, adenocarcinoma with mixed subtype in 11 cases, invasive adenocarcinoma in five cases, other non-small cell carcinoma in 10 cases, and small cell carcinoma in one case. Accumulated 10-year hazard ratio of above histology was 2.4, 2.5, 2.6, 4.1, and 0.7. In multivariate analyses, pathological stage was related to only tumor size (standardized regression coefficient beta = 0.59, p < 0.001) whereas histology was related to tumor size (beta = 0.43, p < 0.001) and smoking index (beta = 0.28, p = 0.016). Conclusions: These results provide direct evidence of a stage-size relationship in long-term repeated CT screening for lung cancer. Furthermore, early detection of lung cancer of 15 mm or less in diameter leads to the detection of early-stage (N0M0) lung cancer in repeated CT screening. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Seki
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - K. Eguchi
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - M. Kaneko
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - H. Ohmatsu
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - R. Kakinuma
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - E. Matsui
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - M. Kusumoto
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - T. Tsuchida
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - H. Nishiyama
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - N. Moriyama
- Teikyo University School of Medicine, Tokyo, Japan; National Cancer Center Hospital (NCCH), Tokyo, Japan; NCCH East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| |
Collapse
|
5
|
Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N. Individualizing the benefit of repeated screening with low-dose helical CT for lung cancer: Update of Anti-Lung Cancer Association project. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N. What we could know from the semiannually repeated screening with low-dose helical CT in a high-risk cohort over 10 years: Update of Anti-Lung Cancer Association project. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7568 Background: There have been several randomized trials of low-dose helical CT (LDCT) screening for lung cancer. However, all trials are in progress. Therefore, before they are completed, we summarized what we could know from an update of Anti-Lung Cancer Association project, which was regarded as a longer-term study with LDCT performed at shorter intervals and with a larger number of detected cancers than any other single-armed studies. Methods: Among 2,120 participants, 1,877 (mean age 64 years, 88% male, and 84% smoker) underwent semiannually repeated screening from 1993 to 2004 (median, 3.5 years). We investigated (1) survival of patients with screening detected lung cancers, (2) presence of a stage shift (indicator of a mortality benefit), (3) appropriate duration of repeated screening, (4) identification of high-risk group by age, sex, and smoking, and (5) appropriate screening intervals by high-risk group (6 months or 1 year). Results: (1) The 5- and 10-year survival rates were 84.5% and 84.5%, respectively, in repeated screening group (n = 57) and were 68.7% and 38.1%, respectively, in initial screening group (n = 19) (P = 0.208). (2) Only in invasive adenocarcinoma, both proportion of stage II to IV and tumor size were negatively correlated with duration of repeated screening (r = −0.77, P = 0.007 and r = − 0.60, P = 0.029, respectively). (3) Detection rate of all incidence cancers were positively correlated with duration of repeated screening (r = 0.50, P = 0.020). However, detection rate remained unchanged until 5 years of repeated screening. Moreover, stage shift did not occur until 5 years of repeated screening. (4) Female sex (HR 2.9, P = 0.015) and smoking (HR 2.7, P = 0.046) were demographic risk factors for lung cancer detection at repeated screening. The accumulated 10-year detection rates for female smokers (n = 91), male smokers (n = 1,557), and non-smokers (n = 229) were 15.1%, 6.2%, and 4.3%, respectively (P = 0.002). (5) The estimated relative cancer detection powers of annual screening to semiannual screening were 50% and 57% for female and male smokers with lung cancer, respectively. Conclusions: Semiannually repeated LDCT screening over 5 years might be beneficial to smokers, especially female smokers. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Seki
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - K. Eguchi
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - M. Kaneko
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - H. Ohmatsu
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - R. Kakinuma
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - E. Matsui
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - M. Kusumoto
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - T. Tsuchida
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - H. Nishiyama
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - N. Moriyama
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| |
Collapse
|
7
|
Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N. The adenocarcinoma-specific stage shift: Closely-repeated low-dose helical CT screening in a high-risk cohort for 10 years. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1006 Background: Trials of CT screening for lung cancer have not yet proven the presence of a stage shift, to say nothing of a mortality benefit. On the basis of an update from Anti-Lung Cancer Association project, we investigated whether the stage shift did occur during the long-term closely-repeated low-dose helical CT screening in a high-risk cohort. Methods: A total of2,120 participants (mean age 63 yrs, 87% male, and 83% smoker) underwent low-dose helical CT screening semiannually from 1993 to 2004 (median, 3.5 years). Results: Nineteen prevalence and 57 incidence lung cancers were detected. In comparison between baseline and repeated screening, the detection rate was 0.90% vs. 0.32% (P < 0.001) and the tumor size was 24mm vs. 17mm (P = 0.018). Adenocarcinoma (74% and 63%) and stage IA (58% and 79%) were observed most commonly in both screen-groups, respectively, but their proportions showed no significant difference between groups, respectively. Regarding the survival of lung cancer patients, screening type was not a significant prognostic factor. In repeated screening,the detection rate oflung cancer except bronchioloalveolar carcinoma increased significantly depending on CT repeating times (r = 0.50, P = 0.020). Moreover, the proportion of stage II-IV and the tumor size decreased significantly only in invasive adenocarcinoma (r = -0.77, P = 0.007 and r = -0.60, P = 0.029, respectively). Conclusions: The adenocarcinoma-specific stage shift did occur in a high-risk cohort. Considering larger proportion of adenocarcinoma in this population, smokers might benefit from the long-term closely-repeated low-dose helical CT screening. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Seki
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - K. Eguchi
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - M. Kaneko
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - H. Ohmatsu
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - R. Kakinuma
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - E. Matsui
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - M. Kusumoto
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - T. Tsuchida
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - H. Nishiyama
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| | - N. Moriyama
- Tokai University School of Medicine, Kanagawa, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Anti-Lung Cancer Association, Tokyo, Japan; Social Health Insurance Medical Center, Tokyo, Japan
| |
Collapse
|
8
|
Yoh K, Kubota K, Kakinuma R, Ohmatsu H, Goto K, Niho S, Nishiwaki Y, Saijo N. A phase II trial of paclitaxel plus carboplatin in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17103 Background: The purpose of this phase II trial was to evaluate the efficacy and toxicity of paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Methods: Eligible patients were aged 20 to 75 years with a performance status (PS) 0 to 1, previous treatment with one or two prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Paclitaxel 200 mg/m2 was infused over 3 hours, before carboplatin (area under the curve 6; Calvert formula) infused over 1 hour, once every 3 weeks for six cycles maximum. The primary endpoint of this study was response rate. Simon’s two-stage design was used to determine the sample size and the planned accrual was 30 patients. Results: Thirty patients were enrolled. Complete response was observed in one patient and partial response in eleven patients for an overall response rate of 40% (95% confidence interval: 23–59%). The median time to progression was 5 months. The median survival was 9.9 months (range, 2.5–33.8 months), and the 1-year survival rate was 46%. The hematologic toxicities were 7% for grade 4 neutropenia, 3% for grade 3 febrile neutropenia, 17% for grade 3 and 4 anemia, and 7% for grade 3 thrombocytopenia. Grade 3 non-hematologic toxicities included rash (7%), myalgia/arthralgia (3%), arrhythmia (3%), and infection (3%). There were no toxic deaths. Conclusions: The combination of paclitaxel plus carboplatin is an active and well-tolerated regimen in the treatment of patients with NSCLC previously treated with chemotherapy who have a good PS. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Yoh
- National Cancer Center Hospital East, Kashiwa, Japan
| | - K. Kubota
- National Cancer Center Hospital East, Kashiwa, Japan
| | - R. Kakinuma
- National Cancer Center Hospital East, Kashiwa, Japan
| | - H. Ohmatsu
- National Cancer Center Hospital East, Kashiwa, Japan
| | - K. Goto
- National Cancer Center Hospital East, Kashiwa, Japan
| | - S. Niho
- National Cancer Center Hospital East, Kashiwa, Japan
| | - Y. Nishiwaki
- National Cancer Center Hospital East, Kashiwa, Japan
| | - N. Saijo
- National Cancer Center Hospital East, Kashiwa, Japan
| |
Collapse
|
9
|
Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N. P-274 The decreased detection rate and the stage shift in lung adenocarcinoma during long-term repeat low-dose helical CT screening. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80768-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Goto K, Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Niho S, Kodama T, Shinkai T, Tamura T, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Yoshida K, Sugiura T, Matsui K, Saijo N. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 2004; 91:659-65. [PMID: 15280919 PMCID: PMC2364791 DOI: 10.1038/sj.bjc.6602056] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Irinotecan (CPT-11) has been shown to exhibit excellent antitumour activity against small-cell lung cancer (SCLC). A multi-institutional phase II study was therefore conducted to evaluate the efficacy and toxicity of CPT-11 combined with cisplatin (CDDP) and etoposide (ETOP) (PEI regimen) for the treatment of sensitive relapsed SCLC. Patients who responded to first-line chemotherapy but relapsed more than 8 weeks after the completion of first-line therapy (n=40) were treated using the PEI regimen, which consisted of CDDP (25 mg m−2) weekly for 9 weeks, ETOP (60 mg m−2) for 3 days on weeks 1, 3, 5, 7, and 9, and CPT-11 (90 mg m−2) on weeks 2, 4, 6, and 8 with granulocyte colony-stimulating factor support. Five complete responses and 26 partial responses were observed, and the overall response rate was 78% (95% confidence interval 61.5–89.2%). The median survival time was 11.8 months, and the estimated 1-year survival rate was 49%. Grade 3/4 leucocytopenia, neutropenia, and thrombocytopenia were observed in 55, 73, and 33% of the patients, respectively. Nonhaematological toxicities were mild and transient in all patients. In conclusion, the PEI regimen is considered to be highly active and well tolerated for the treatment of sensitive relapsed SCLC.
Collapse
Affiliation(s)
- K Goto
- Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Nishiwaki Y. First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7059] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Niho
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Kubota
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Goto
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Yoh
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - H. Ohmatsu
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - R. Kakinuma
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Y. Nishiwaki
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| |
Collapse
|
12
|
Kim YH, Goto K, Ishii G, Kakinuma R, Kubota K, Ohmatsu H, Niho S, Nagai K, Nishiwaki Y, Ochiai A. Association of papillary subtype of lung adenocarcinoma with response to gefitinib. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Y. H. Kim
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Goto
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - G. Ishii
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - R. Kakinuma
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Kubota
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - H. Ohmatsu
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - S. Niho
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Nagai
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Y. Nishiwaki
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - A. Ochiai
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| |
Collapse
|
13
|
Goto K, Kim E, Kubota K, Niho S, Kakinuma R, Ohmatsu H, Yoh K, Nagai K, Nishiwaki Y. Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Goto
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - E. Kim
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Kubota
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - S. Niho
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - R. Kakinuma
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - H. Ohmatsu
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Yoh
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K. Nagai
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Y. Nishiwaki
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| |
Collapse
|
14
|
Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y. A randomized trial of 6-minutes drip infusion versus 1-minute bolus injection of vinorelbine (VNR) for the control of drug induced-phlebitis. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Yoh
- National Cancer Center Hospital East, Kashiwa, Japan
| | - S. Niho
- National Cancer Center Hospital East, Kashiwa, Japan
| | - K. Goto
- National Cancer Center Hospital East, Kashiwa, Japan
| | - H. Ohmatsu
- National Cancer Center Hospital East, Kashiwa, Japan
| | - K. Kubota
- National Cancer Center Hospital East, Kashiwa, Japan
| | - R. Kakinuma
- National Cancer Center Hospital East, Kashiwa, Japan
| | - Y. Nishiwaki
- National Cancer Center Hospital East, Kashiwa, Japan
| |
Collapse
|
15
|
Ohe Y, Niho S, Kakinuma R, Kubota K, Ohmatsu H, Goto K, Nokihara H, Kunitoh H, Saijo N, Aono H, Watanabe K, Tango M, Yokoyama A, Nishiwaki Y. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004; 15:45-50. [PMID: 14679118 DOI: 10.1093/annonc/mdh015] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND To evaluate the efficacy and safety of treatments for advanced non-small-cell lung cancer in elderly patients aged 75 years or older, we conducted a phase II study of cisplatin and docetaxel administered in three consecutive weekly infusions. PATIENTS AND METHODS The eligibility criteria for the study included the presence of chemotherapy-naive advanced non-small-cell lung cancer, age > or =75 years, Eastern Cooperative Oncology Group performance status of 0 or 1, a measurable lesion, adequate organ functions and signed informed consent. The chemotherapy regimen consisted of cisplatin (25 mg/m(2)) and docetaxel (20 mg/m(2)) on days 1, 8 and 15 every 4 weeks. RESULTS Between February 2000 and March 2002, 34 elderly patients with non-small-cell lung cancer were enrolled in the study and 33 patients were treated. Two complete responses and 15 partial responses were obtained for an objective response rate of 52% in 33 treated patients. The median survival period was 15.8 months, and the 1-year survival rate was 64%. Toxicities were mild with no grade 4 toxicities. Only grade 3 leukopenia (6%), neutropenia (12%), anemia (3%), hyponatremia (3%) and nausea/vomiting (3%) were observed. CONCLUSION Cisplatin and docetaxel administered in three consecutive weekly infusions was safe and effective for the treatment of elderly patients with chemotherapy-naive non-small-cell lung cancer.
Collapse
Affiliation(s)
- Y Ohe
- Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Minegishi Y, Ohmatsu H, Miyamoto T, Niho S, Goto K, Kubota K, Kakinuma R, Kudoh S, Nishiwaki Y. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis. Eur J Cancer 2004; 40:1188-92. [PMID: 15110882 DOI: 10.1016/j.ejca.2004.01.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2003] [Revised: 01/15/2004] [Accepted: 01/20/2004] [Indexed: 11/25/2022]
Abstract
We conducted a prospective, randomized, double-blind, parallel study comparing the antiemetic activity and tolerability of treatment with droperidol (2.5 mg d.i.v. twice daily for 5 days) and placebo, both combined with granisetron (3 mg d.i.v. on the first day) and dexamethasone (16 mg d.i.v. on the first day, 8 mg d.i.v. on days 2, 3, and 4 mg d.i.v. on days 4, 5). A total of 180 lung cancer patients receiving high-dose cisplatin (80 mg/m(2))-containing chemotherapy were enrolled in the study, and 171 of them were capable of being evaluated. The clinical characteristics of the patients in the two treatment arms were well balanced. Complete protection from nausea and vomiting was recorded in the acute phase in 97% of patients who treated with droperidol versus 98% of patients who given the placebo (P=0.920), and in 42% versus 38% in the delayed phase (P=0.615). The multiple logistic regression analysis showed that a history of motion sickness was a significant risk factor for cisplatin-induced delayed emesis (odds ratio [OR]=5.98; 95% CI=2.15 to 16.7, P=0.0006). Droperidol-containing treatment was well tolerated by most patients, however, the incidence of sleepiness in the droperidol group was higher than in the placebo group (69% versus 30%, P<0.0001). In conclusion, our data did not support the hypothesis that addition of droperidol to granisetron and dexamethasone reduces the delayed emesis induced by high-dose cisplatin.
Collapse
Affiliation(s)
- Y Minegishi
- Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, 277-8577, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Ishikura S, Ohe Y, Nihei K, Kubota K, Kakinuma R, Ohmatsu H, Goto K, Niho S, Nishiwaki Y, Ogino T. 779 A pilot study of hyperfractionated accelerated radiotherapy (HART) following induction cisplatin and vinorelbine for stage III non-small cell lung cancer (NSCLC). EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90804-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
18
|
Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Goto K, Kodama T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Kunitoh H, Yoshimura K, Saijo N. Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Br J Cancer 2003; 88:808-13. [PMID: 12644814 PMCID: PMC2377075 DOI: 10.1038/sj.bjc.6600800] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Combinations of cisplatin-irinotecan and cisplatin-etoposide are active and well tolerated in patients with both small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC). To define the recommended dose for phase II trials of irinotecan combined with cisplatin and etoposide in chemonaive patients with stage IV disease, 56 patients (11 having SCLC and 45 NSCLC) received cisplatin 25 mg m(-2) weekly for 9 weeks, etoposide 60 mg m(-2) for 3 days on weeks 1, 3, 5, 7 and 9, and irinotecan 20-100 mg m(-2) (levels 1-8) on weeks 2, 4, 6 and 8, together with a prophylactical granulocyte colony-stimulating factor support (50 microg m(-2) on days 4-7 on weeks 1, 3, 5, 7 and 9, and on days 2-7 on weeks 2, 4, 6 and 8). Grade 3-4 leukocytopenia, neutropenia and thrombocytopenia were noted in 20 (36%), 28 (50%) and nine (16%) patients, respectively. Grade 3 diarrhoea, grade 3 cardiac toxicity, and grade 4 transaminase elevation developed in one (1.8%) patient each. Totally, four of 56 patients were removed from the study because of toxicity and recovered, and two other patients died in situations where drug toxicity might contribute to their death. Dose-limiting toxicity was noted in less than one-third of patients at dose levels 1-7, but in all patients at dose level 8. Thus, the recommended dose was determined to be level 7 (irinotecan 90 mg m(-2)). The response rates for SCLC and NSCLC were 91% (10/11) and 38% (17/45), respectively. The median survival time and 1-year survival rate were 11.9 months and 46% for SCLC and 10.1 months and 40% for NSCLC, respectively. This regimen was considered to be feasible and promising for the treatment of stage IV SCLC and NSCLC.
Collapse
Affiliation(s)
- I Sekine
- Internal Medicine and Thoracic Oncology Division, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, Nishiwaki Y. Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study. Br J Cancer 2002; 87:1360-4. [PMID: 12454762 PMCID: PMC2376298 DOI: 10.1038/sj.bjc.6600658] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2002] [Revised: 09/17/2002] [Accepted: 09/21/2002] [Indexed: 11/29/2022] Open
Abstract
We conducted a phase II trial of triplet chemotherapy consisting of vinorelbine, gemcitabine, and cisplatin in patients with advanced non-small cell lung cancer to assess its efficacy and toxicity. Thirty-three patients with chemotherapy-naïve stage IIIB disease (n=8), stage IV disease (n=23), or recurrence after surgical resection (n=2) were given intravenous infusions of vinorelbine 25 mg m(-2), gemcitabine 1000 mg m(-2), and cisplatin 40 mg m(-2) on days 1 and 8 at 3-week intervals. There were 16 partial responses, and the objective response rate was 48% (95% confidence interval: 31-66%). The median survival time was 13.5 months (95% confidence interval: 10.6-16.4 months), and the one-year survival rate was 61%. Grade 4 haematologic toxicity consisted of neutropenia in 72% of patients, and febrile neutropenia occurred in 42% of the patients. There was one toxic death, and it was attributed to neutropenic fever and haemoptysis. Autopsy revealed diffuse pulmonary haemorrhage secondary to bacterial abscesses and vasculitis in both lungs. The common nonhaematologic toxicities included grade 2-3 nausea (39%) and vomiting (18%). Triplet chemotherapy containing vinorelbine, gemcitabine, and cisplatin is effective in the treatment of chemo-näive patients with advanced non-small cell lung cancer, but produces unacceptable frequent febrile neutropenia.
Collapse
Affiliation(s)
- S Niho
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa, Chiba 277-8577, Japan.
| | | | | | | | | | | | | |
Collapse
|
20
|
Goto K, Kodama T, Sekine I, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Ikeda H, Ando M, Nishiwaki Y. Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer 2001; 34:141-8. [PMID: 11557124 DOI: 10.1016/s0169-5002(01)00215-x] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The antigen KL-6, a mucin-like high-molecular-weight glycoprotein, is expressed on type-2 pneumocytes and bronchiolar epithelial cells. Serum levels of KL-6 have been shown to correlate well with the activities of several different kinds of interstitial pneumonia. The purpose of this study was to assess the usefulness of monitoring serum KL-6 levels in patients who had received thoracic radiotherapy (TRT). In particular, the usefulness of such a protocol for the early diagnosis of severe radiation pneumonitis (RP) and the evaluation of its progress and severity was examined. Serum KL-6 levels were retrospectively monitored in 16 patients with lung cancer who had received TRT with or without chemotherapy. Eight of these patients had developed severe RP and eight had developed localized (within the irradiated field) RP. Serum KL-6 levels were measured using a modified sandwich-type enzyme-linked immunosorbent assay. In patients who developed severe RP, serum KL-6 levels showed a consistent tendency to increase after the clinical diagnosis of RP. In four patients, serum KL-6 levels even began to rise before a clinical diagnosis of severe RP had been made. In the patients with localized RP, on the other hand, the serum levels did not show any tendency to increase during or after TRT. Moreover, patients whose serum KL-6 levels rose more than 1.5 times higher than their pre-treatment serum KL-6 level, had a large chance of developing severe RP that was unresponsive to steroid hormones and resulted in death. Serum KL-6 levels, therefore, should be useful indicators for the early diagnosis of severe RP and for estimating its progress and severity in patients treated with TRT.
Collapse
Affiliation(s)
- K Goto
- Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha Kashiwa Chiba 277-8577, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ishibashi F, Mizukami T, Kanegasaki S, Motoda L, Kakinuma R, Endo F, Nunoi H. Improved superoxide-generating ability by interferon gamma due to splicing pattern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene. Blood 2001; 98:436-41. [PMID: 11435314 DOI: 10.1182/blood.v98.2.436] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Chronic granulomatous disease (CGD) is an inherited disorder of host defense against microbial infections caused by defective activity of the phagocyte NADPH oxidase. Based on an increase of neutrophil superoxide-generating ability in response to interferon gamma (IFN-gamma) in a single patient with CGD, multicentered group studies demonstrated a beneficial effect of prophylactic IFN-gamma. However, no apparent increase of the phagocyte superoxide generation was found in patients enrolled in these studies. The present report offers an additional kindred in whom an IFN-gamma-dependent increase in neutrophil superoxide production was observed in 3 affected patients. The defect in the CYBB gene for gp91-phox was identified as an otherwise silent mutation adjacent to the third intron of the CYBB gene that alters messenger RNA splicing. By molecular analysis, significant differences were found in the splicing pattern of CYBB gene transcripts in patient neutrophils between 1 and 25 days after administration of IFN-gamma. Furthermore, a complete transcript containing the missing exons could be detected in all specimens after the treatment. The changes in the splicing pattern of the transcripts and the prolonged effect on superoxide-generating ability of patient neutrophils indicate that IFN-gamma induced a partial correction of the abnormal splicing of CYBB gene transcripts in myeloid progenitor cells.
Collapse
Affiliation(s)
- F Ishibashi
- Department of Pediatrics, Kumamoto University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
22
|
Ohe Y, Niho S, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Goto K, Kunitoh H, Saijo N, Nishiwaki Y. Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn J Clin Oncol 2001; 31:100-6. [PMID: 11336320 DOI: 10.1093/jjco/hye019] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND To determine the maximum tolerated dose and recommended dose of cisplatin and docetaxel administered by three consecutive weekly infusions in both non-elderly (< or =74 years) and elderly (> or =75 years) patients, we conducted two independent phase I studies for nonelderly and elderly patients with non-small cell lung cancer. METHODS Between April 1998 and September 1999, 26 non-elderly (median, 54 years; range, 44-73 years) and 12 elderly (median, 76 years; range, 75-80 years) patients with non-small cell lung cancer were entered in these studies. The eligibility criteria of both cohorts were identical except for age. Chemotherapy consisted of cisplatin 25 mg/m2 and an escalated dose of docetaxel on days 1, 8 and 15 every 4 weeks. The initial dose of docetaxel was 20 mg/m2 and it was increased by 5 mg/m2 at each dose level. RESULTS In the non-elderly and elderly cohorts, up to 45 or 25 mg/m2 of docetaxel, respectively, were administered. Dose-limiting toxicities were neutropenia, liver damage, pneumonia and omission of treatment on day 15 by leukopenia and refusal in the non-elderly cohort; pneumonia and omission of treatment on day 15 by refusal due to fatigue/asthenia or fever in the elderly cohort. We considered the recommended doses for phase II studies were cisplatin 25 mg/m2 and docetaxel 35 mg/m2 on days 1, 8 and 15 for non-elderly patients and cisplatin 25 mg/m2 and docetaxel 20 mg/m2 on days 1, 8 and 15 for elderly patients. Seven of 26 (27%) and seven of 12 (58%) patients achieved a partial response, median survival times were 8.7 and 7.2 months and 1 year survival rates were 27 and 27% in the non-elderly and elderly cohorts, respectively. CONCLUSIONS Further evaluation of this combination chemotherapy is warranted for both nonelderly and elderly patients with non-small cell lung cancer but the dose of docetaxel should be lower for elderly than non-elderly patients.
Collapse
Affiliation(s)
- Y Ohe
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Kurata T, Tamura T, Shinkai T, Ohe Y, Kunitoh H, Kodama T, Kakinuma R, Matsumoto T, Kubota K, Omatsu H, Nishiwaki Y, Saijo N. Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. Jpn J Clin Oncol 2001; 31:93-9. [PMID: 11336328 DOI: 10.1093/jjco/hye022] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND To establish the toxicities and maximum tolerated dose of paclitaxel given over 3 h in combination with cisplatin, to determine the pharmacokinetic profiles of these two drugs and to observe their antitumor activity, we conducted a combination phase I study in non-small cell lung cancer. METHODS Patients received paclitaxel doses of 150-210 mg/m2 given over 3 h and cisplatin doses of 60-80 mg/m2 as a 1 h infusion 2 h after the end of the paclitaxel infusion. RESULTS A total of 25 patients with previously untreated non-small cell lung cancer were enrolled. Granulocytopenia was the most frequent hematological toxicity and the most prominent non-hematological toxicity was sensory dominant neuropathy. Two of six patients experienced dose limiting toxicities (leukopenia, infection and neuropathy) at a dose of paclitaxel 210 mg/m2 and cisplatin 60 mg/m2, which was considered the maximum tolerated dose. There were seven partial responses among 24 evaluable patients, for an overall response rate of 29%. The median survival time was 341 days and the 1 year survival rate was 45.8%. As the paclitaxel pharmacokinetic parameters in this study were consistent with those of our previous single agent study, we found no significant drug-drug interaction between the 3 h infusion paclitaxel and cisplatin. CONCLUSION The recommended doses for further study are determined to be paclitaxel 180 mg/m2 and cisplatin 80 mg/m2. This is a well-tolerated and active regimen for non-small cell lung cancer. In view of the promising survival outcome, further evaluation in prospective randomized trials versus other regimens is warranted.
Collapse
Affiliation(s)
- T Kurata
- Thoracic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Kawasaki H, Nagai K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Suzuki K, Kakinuma R, Nishiwaki Y. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 2001; 76:53-7. [PMID: 11223825 DOI: 10.1002/1096-9098(200101)76:1<53::aid-jso1009>3.0.co;2-t] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND AND OBJECTIVES Idiopathic pulmonary fibrosis (IPF) is well known to be associated with lung cancer. It is important to clarify the clinical and pathological features of lung cancer with IPF in understanding the pathogenesis of lung cancer in IPF patients. We compared clinicopathological factors of lung cancer in patients with and without IPF. METHODS A retrospective study was conducted in 711 surgically resected lung cancer patients. Medical records were compared of IPF and non-IPF patients. RESULTS Of the 711 patients, 53 (7.5%) were IPF patients. Lung cancer in IPF patients was more frequent in elderly male smokers. Most lung cancers in IPF (79%) arose in peripheral areas involving fibrosis (P < 0.01). The incidence of squamous cell carcinoma in the IPF patients (46%) was significantly higher than that in non-IPF patients (22%) (P < 0.01). The incidence of multiple lung cancer in IPF cases (17%) was also significantly higher. CONCLUSIONS These results suggest that IPF has the potential to develop into lung cancer, especially peripheral squamous cell carcinoma. Further molecular analyses are necessary to clarify the relationship between IPF and lung cancer.
Collapse
Affiliation(s)
- H Kawasaki
- Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ohe Y, Yamamoto S, Suzuki K, Hojo F, Kakinuma R, Matsumoto T, Ohmatsu H, Nishiwaki Y. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 2001; 37:54-63. [PMID: 11165130 DOI: 10.1016/s0959-8049(00)00350-6] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
We retrospectively analysed the incidence and risk factors of treatment-related death in the treatment of chemotherapy- and thoracic radiotherapy-naïve patients with lung cancer. Between July 1992 and December 1997, 1799 patients were diagnosed as having lung cancer in our hospital and 926 patients received chemotherapy and/or thoracic radiotherapy. 25 patients (2.7%) died from toxicity of the treatment, 10 from pneumonia, 7 from radiation pneumonitis, 6 from sepsis, 1 from perforation of the small intestine and 1 for an unknown reason. 18 patients (2.3%) died from chemotherapy-related toxicity. The incidence of treatment-related death (TRD) from chemotherapy was highly correlated with the performance status (PS), PS 0: 0.7%, PS 1: 2.2%, PS 2: 4.0%, PS 3: 7.7% and PS 4: 25% (P=0.004). 7 patients (1.6%) died from pneumonitis after thoracic radiotherapy. Multivariate analyses demonstrated that poor PS (relative risk (RR): 1.95, 95% confidence interval (CI): 1.05-3.65, P=0.034) and chemotherapy using the cisplatin+vindesine+mitomycin C regimen (RR: 9.36, 95% CI: 1.29-68.0, P=0.027) are associated with treatment-related death from chemotherapy. Pulmonary fibrosis identified on a plain chest X-ray film (RR: 165.7, 95% CI: 8.79-3122, P<0.001), the combination of cisplatin+irinotecan (RR: 120.5, 95% CI: 2.90-4993, P=0.012), advanced age (RR: 1.17, 95% CI: 1.002-1.37, P=0.047), and elevated lactate dehydrogenase (LDH) (RR: 10.4, 95% CI: 1.20-90.2, P=0.033) were also associated with treatment-related death from thoracic radiotherapy. The administration of mitomycin C in addition to cisplatin-based regimens for patients with lung cancer should be carefully considered.
Collapse
Affiliation(s)
- Y Ohe
- Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, 6-5-1 Kashiwanoha, Kashiwa-City, 277-8577, Chiba, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
BACKGROUND In Japan, lung carcinoma is the leading cause of cancer-related deaths. Adenocarcinoma accounts for roughly half of all lung carcinomas. Earlier detection of lung carcinoma is expected to reduce mortality rates. Computed tomography (CT) provides higher contrast resolution and greater visualization of chest compartments that are difficult to view with chest radiography, such as the mediastinum. CT further permits the detection of minute peripheral nodules. At present, several institutions and research groups are evaluating the utility of low dose spiral CT for lung carcinoma screening. METHODS From September 1993 to December 1998, 1669 individuals underwent a biannual screening program for lung carcinoma. The program included posteroanterior radiograph, sputum cytology, and low dose spiral CT at a for-profit organization: The Anti-Lung Cancer Association (ALCA). A total of 9993 examinations were carried out. The low dose spiral CT parameters used were 120 kvP, 50 mA, 10-mm collimation, and 2:1 pitch. RESULTS Peripheral lung carcinoma was detected in 31 of 9993 examinations (0.3%). Of the 31 cases, 24 tumors (77%) were detected by low dose spiral CT but were not visible on standard chest radiography. Twenty-two of the 24 tumors were Stage IA (T1N0M0, according to staging system revised in 1997). CONCLUSIONS Low dose spiral CT shows promise for lung carcinoma screening. The effectiveness of the technique for the detection of minute lung lesions remains to be established. Routine use of the technique will require resolution of several issues. These issues include the establishment of CT diagnostic criteria, the development of a diagnostic support system, the establishment of methods for definite diagnosis, and assessments of efficacy.
Collapse
Affiliation(s)
- M Kaneko
- National Cancer Center Hospital, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Niho S, Kubota K, Moriyama E, Hosomi Y, Uramoto H, Nomura M, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, Shinkai T, Nishiwaki Y. Does chemotherapy duration impact on survival in patients with stage IV non-small cell lung cancer? Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80286-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Goto K, Kodama T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Kunitoh H, Yoshimura K, Saijo N. Dose intensity of irinotecan (CPT) combined with weekly cisplatin (DDP) and etoposide (ETOP) in patients (pts) with metastatic lung cancer (LC): Phase I/II study JCOG 9507. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80120-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Kakinuma R, Ohmatsu H, Kaneko M, Kusumoto M, Kenji E, Nishiyuma H, Nagai K, Nishiwaki Y, Moriyama N, Kawata Y, Kiki N. Computer-aided diagnosis of lung cancer by helical CT screening: Retrospective analysis. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80823-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Yoshida J, Nagai K, Nishimura M, Takahashi K, Kakinuma R, Nishiwaki Y, Yokose T. Secretion of hCG/beta-hCG by squamous cell carcinoma of the lung in a 31-year-old female smoker. Jpn J Clin Oncol 2000; 30:163-6. [PMID: 10798545 DOI: 10.1093/jjco/hyd028] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
We describe a rare case of pulmonary squamous cell carcinoma secreting human chorionic gonadotropin (hCG) and its beta-subunit (beta-hCG) in a young female smoker. A 31-year-old mother of one child had been suffering from dysfunctional uterine bleeding for about 1 year. Pelvic examinations and abdominal ultrasonography yielded no abnormal findings and no signs of pregnancy. She developed a pain in the right chest and a huge (12x10 cm) squamous cell carcinoma was diagnosed in the right lower lobe. The serum hCG and beta-hCG levels were high: hCG 5611 mlU/ml (normal upper limit 0.7 mIU/ml), beta-hCG 12 238 mIU/ml (normal upper limit 0.5 mIU/ml). The patient underwent right lower lobectomy and systematic lymph node dissection. Microscopic study showed a poorly differentiated squamous cell carcinoma. The pathological stage was T2N0M0, stage IB. Immunohistochemical staining of the tumor was strongly positive for hCG. The serum hCG level returned to normal 1 month after the operation, while an additional 2 months were necessary for the beta-hCG level to normalize. Dysfunctional uterine bleeding disappeared and the patient is doing well, with no signs of recurrence, 9 months after the resection.
Collapse
Affiliation(s)
- J Yoshida
- Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
| | | | | | | | | | | | | |
Collapse
|
31
|
Niho S, Nishiwaki Y, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Ohe Y, Kakinuma R, Kodama T. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000; 27:159-67. [PMID: 10699689 DOI: 10.1016/s0169-5002(99)00100-2] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) have been reported to be useful markers for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer (SCLC). Recently, pro-gastrin-releasing peptide (Pro-GRP) became available as a sensitive, specific, and reliable tumor marker for patients with SCLC. The aim of this study is to determine the most useful tumor marker to detect the relapse of SCLC. Furthermore, we analyzed the relationship between tumor markers at relapse and survival from relapse or response to salvage chemotherapy. Medical records were reviewed to obtain serum levels of Pro-GRP, NSE, and CEA before and after the initial chemotherapy, and at relapse. Consecutive 66 patients with SCLC, with an objective response and confirmed relapse treated at the National Cancer Center Hospital East, were analyzed in this study. The percentages of patients whose tumor marker level were elevated before treatment, decreased after the treatment, and increased again at relapse were 67% (95% CI, 55-78) for Pro-GRP, 20% (10-29) for NSE, and 38% (26-50) for CEA. Multivariate analysis indicated that poor performance status before initial treatment and elevated serum levels of lactate dehydrogenase at relapse were poor prognostic factors for patients with recurrent SCLC (P<0.005). None of the serum levels of Pro-GRP, NSE, and CEA at relapse was a significant prognostic factor and associated with an objective response to salvage chemotherapy. The present study demonstrated that serum levels of Pro-GRP reflect the disease course of patients with SCLC most accurately.
Collapse
Affiliation(s)
- S Niho
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa, Chiba, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Tanaka K, Shima Y, Kakinuma R, Kubota K, Ohe Y, Hojo F, Matsumoto T, Ohmatsu H, Goto K, Nagai K, Nishiwaki Y. Effect of nebulized morphine in cancer patients with dyspnea: a pilot study. Jpn J Clin Oncol 1999; 29:600-3. [PMID: 10721941 DOI: 10.1093/jjco/29.12.600] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND It is known that opioids may decrease subjective dyspnea. The recent finding that opioid binding sites are present in the peripheral bronchus supports the possibility of a local action of opioids. However, the clinical benefit of nebulized morphine is controversial. The purpose of this study was to confirm the feasibility of nebulized morphine and to evaluate its clinical benefits. PATIENTS AND METHODS Fifteen cancer patients with dyspnea in the Thoracic Oncology Division and Palliative Care Unit in the National Cancer Center Hospital East were given 20 mg of morphine hydrochloride dissolved in 5 ml of normal saline through an ultranebulizer. The subjective effects were evaluated using a visual analog scale (VAS) immediately before and 60 min after inhalation. Respiratory rate (RR), hemoglobin oxygen saturation (SpO2) and blood pressure also were measured twice at these two time points. A questionnaire about adverse reactions was included. RESULTS No major adverse reactions such as respiratory depression, sleepiness, nausea or vomiting were observed. VAS was significantly decreased after nebulization (p = 0.005) without any significant change in RR or SpO2. In eight of 15 patients, dyspnea was improved as measured by a decrease in VAS of more than 10%. This correlated with the desire of the patients to continue its use. CONCLUSION Our preliminary data confirmed the feasibility of nebulized morphine and suggested its possible clinical benefit for dyspneic patients. A randomized controlled study is warranted to exclude a placebo effect and to compare the clinical benefits of nebulized morphine with those of other methods of treatment.
Collapse
Affiliation(s)
- K Tanaka
- Thoracic Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Hosomi Y, Ohe Y, Mito K, Uramoto H, Moriyama E, Tanaka K, Kodama K, Niho S, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Kakinuma R, Nishiwaki Y. Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer. Jpn J Clin Oncol 1999; 29:546-9. [PMID: 10678557 DOI: 10.1093/jjco/29.11.546] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Docetaxel, cisplatin and mitomycin C are some of the active drugs used in the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The purpose of this study was to determine the maximum tolerated dose (MTD) and recommended dose of the three drugs in combination for such patients. METHODS Chemotherapy-native patients with metastatic NSCLC were enrolled in this study. The doses of docetaxel and cisplatin were fixed at 60 and 80 mg/m2, respectively. It was planned to increase the dose of mitomycin C from 4 to 6 and 8 mg/m2. All drugs were administered on day 1 and repeated every 3-4 weeks. RESULTS All six patients received 60 mg/m2 of docetaxel and 80 mg/m2 of cisplatin, three of them with 4 mg/m2 of mitomycin C (level 1) and the other three with 6 mg/m2 of mitomycin C (level 2). Two of the three level 2 patients experienced dose-limiting toxicities (DLTs) in first cycle: febrile neutropenia and grade 3 hyponatremia. Based on these data, the MTD was concluded to be 60 mg/m2 for docetaxel, 80 mg/m2 for cisplatin and 6 mg/m2 for mitomycin C. Evaluation of the data from all of the cycles, however, showed that four of the six patients experienced DLTs. CONCLUSIONS The addition of mitomycin C to docetaxel and cisplatin resulted in relatively high toxicities. It was impossible to use a high enough dose of mitomycin C to improve the survival of NSCLC patients. We therefore concluded that further evaluation of this combination is unwarranted.
Collapse
Affiliation(s)
- Y Hosomi
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Kakinuma R, Ohmatsu H, Kaneko M, Eguchi K, Naruke T, Nagai K, Nishiwaki Y, Suzuki A, Moriyama N. Detection failures in spiral CT screening for lung cancer: analysis of CT findings. Radiology 1999; 212:61-6. [PMID: 10405721 DOI: 10.1148/radiology.212.1.r99jn1461] [Citation(s) in RCA: 95] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To clarify the computed tomographic (CT) findings and the progression of minute lung cancers that were missed at initial spiral CT screening but were later detected. MATERIALS AND METHODS The findings from seven patients with lung cancer that was missed at the initial spiral CT screening were reviewed. Retrospective CT findings, time to detection, cell type, and pathologic stage were evaluated. RESULTS Minute lung cancers missed at early spiral CT included a nodule among the shadows of old tuberculosis (n = 2), a faint nodule with high attenuation in the center of the nodule (n = 1), an increase in attenuation just adjacent to an axial peripheral pulmonary vessel (n = 1) and adjacent to a craniocaudal peripheral pulmonary vessel (n = 1), and a minute faint nodule (n = 2). The time to detection ranged from 6 to 18 months. At pathologic examination, six cancers were stage I, and one was stage II. CONCLUSION Minute nodules of lung cancer that are near the threshold of detectability may be missed at spiral CT screening. It is important to examine noncalcified nodules with thin-section CT even when lesions from prior disease, such as those from old tuberculosis, exist and to evaluate the shadows of pulmonary vessels carefully. A follow-up examination is highly recommended.
Collapse
Affiliation(s)
- R Kakinuma
- Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Ogawa Y, Shimizu H, Itakura Y, Ohama Y, Arakawa H, Amizuka T, Obata M, Kakinuma R. Functional pulmonary surfactant deficiency and neonatal respiratory disorders. Pediatr Pulmonol Suppl 1999; 18:175-7. [PMID: 10093135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
The pathophysiology of functional deficiency of pulmonary surfactant in the neonatal respiratory disorders represented by MAS, hemorrhagic lung edema and ARDS was discussed. The removal of inhibitor(s) is the cardinal procedure for MAS and the lavage with surfactant solution seems to be promising. In case of replacement therapy, we should consider using a different dose compared to the one used in RDS due to lung immaturity, in order to optimize results.
Collapse
Affiliation(s)
- Y Ogawa
- Department of Pediatrics Saitama Medical Center, Saitama Medical School, Kawagoe, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Goto K, Kodama T, Hojo F, Kubota K, Kakinuma R, Matsumoto T, Ohmatsu H, Sekine I, Nagai K, Nishiwaki Y. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer 1998; 82:1056-61. [PMID: 9506349 DOI: 10.1002/(sici)1097-0142(19980315)82:6<1056::aid-cncr7>3.0.co;2-c] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Progastrin-releasing peptide (proGRP) is a specific tumor marker in patients with small cell lung carcinoma (SCLC). It has been reported that serum proGRP levels rarely are elevated in patients with nonsmall cell lung carcinoma (NSCLC); the reported frequency is <3%. The purpose of this study was to examine the clinicopathologic features of NSCLC patients with high serum proGRP levels. METHODS The authors measured serum proGRP levels with a TND-4 kit, a newly developed enzyme-linked immunoadsorbent assay, in 544 NSCLC and 206 SCLC patients. Pathologic features were examined using conventional hematoxylin and eosin staining and histochemical and immunohistochemical staining using polyclonal antibodies to proGRP, chromogranin A, calcitonin, and monoclonal antibody to the neural cell adhesion molecule (NCC-Lu-243). RESULTS The serum proGRP levels were elevated in 140 SCLC patients (68.0%) and in 23 NSCLC patients (4.2%). Seven of these 23 NSCLC patients had serum proGRP levels > or = 100 pg/mL. They included two patients with renal dysfunction, one patient diagnosed cytologically with adenocarcinoma without undergoing precise pathologic examination, two patients diagnosed histologically with squamous cell carcinoma with foci of small cell elements, and two patients diagnosed with large cell neuroendocrine carcinoma and poorly differentiated adenocarcinoma, respectively, which showed neuroendocrine differentiation on immunohistologic analysis. The remaining 16 NSCLC patients had serum proGRP levels < 70 pg/mL. CONCLUSIONS Nearly all NSCLC patients had serum proGRP levels < 100 pg/mL. However, if an NSCLC patient presents with a proGRP level > or = 100 pg/mL, the clinicopathologic features must be examined with regard to the small cell component, neuroendocrine differentiation, and renal dysfunction.
Collapse
Affiliation(s)
- K Goto
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Kanazawa K, Kawata Y, Niki N, Satoh H, Ohmatsu H, Kakinuma R, Kaneko M, Moriyama N, Eguchi K. Computer-aided diagnosis for pulmonary nodules based on helical CT images. Comput Med Imaging Graph 1998; 22:157-67. [PMID: 9719856 DOI: 10.1016/s0895-6111(98)00017-2] [Citation(s) in RCA: 163] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In this paper, we present a computer-assisted automatic diagnostic system for lung cancer that detects nodule candidates at an early stage from helical CT images of the thorax. Our diagnostic system consists of analytical and diagnostic procedures. In the analytical procedure, first we extract the lung and the pulmonary blood vessel regions using the fuzzy clustering algorithm, then we analyze the features of these regions using image-processing techniques. In the diagnostic procedure, we define diagnostic rules utilizing the extracted features which support the determination of the candidate nodule locations. We show the effectiveness of our system by giving the results from its application to image data for mass screening of 450 patients.
Collapse
Affiliation(s)
- K Kanazawa
- Department of Optical Science, University of Tokushima, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Miyamoto T, Ohmatsu H, Kakinuma R, Kodama T, Nishiwaki Y, Nagai K, Moriyama N. 848 CT fluoroscopically guided transthoracic needle biopsy. Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)80226-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Goto K, Kodama T, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Sekine I, Nishiwaki Y. 879 Monitoring serum KL-6: A useful indicator for interstitial pneumonia due to radiotherapy and chemotherapy in patients with lung cancer. Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)80260-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Nishiyama H, Tadera M, Suzuki S, Tuchiya S, Yamaguchi T, Hayashi N, Kato S, Suzuki A, Sobue T, Ohmatsu H, Kakinuma R, Moriyama N, Eguchi K, Kaneko M, Naruke T. 762 Usefulness of helical CT scan for early detection of lung cancer our experience at the anti-lung cancer association (ALCA). Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)80140-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Ogino H, Yokoyama A, Saito M, Mori K, Tsukiyama I, Tsuchiya S, Hayakawa K, Saijo N. 303 Phase II study of alternating radiotherapy (RT) and chemotherapy (CT) for locally advanced non-small-cell lung cancer (NSCLC). JCOG study 9306. Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)89687-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Kakinuma R, Ohmatsu H, Kaneko M, Eguchi K, Naruke T, Nagai K, Nishiwaki Y, Kodama T, Moriyama N. 829 Lung cancer detected by helical CT screening: Review of retrospectively visible cases. Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)80211-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Ebi N, Kubota K, Nishiwaki Y, Hojo F, Matsumoto T, Kakinuma R, Ohmatsu H, Sekine I, Yokosaki M, Gotoh K, Yamamoto H, Kodama T. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997; 27:166-9. [PMID: 9255271 DOI: 10.1093/jjco/27.3.166] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Between January 1985 and August 1991, 159 patients with small cell lung cancer received first-line chemotherapy and 123 (77%) were responders. Of these, 88 relapsed, the remainder having died of other or unknown diseases or being alive without carrying cancer. The relapsed patients were examined to evaluate the outcome of the treatment for relapsed small cell lung cancer and to identify the factors that would contribute to the response rates and the survival durations. Forty-eight of 88 relapsed patients received second-line chemotherapy. Of the 48, 3 were evaluated as showing a complete response, 13 as partial response, 9 as no change, 15 as progressive disease and 8 as not evaluable. The response rate was 33% (95% confidence interval 20.4-48.4%). The median survival time was 146 days. The duration and rate of response in first-line chemotherapy affected the response rates of the second-line chemotherapy, but without statistical significance (P = 0.058 and 0.067 respectively). Increased response duration, time off chemotherapy and previous response to first-line chemotherapy all had a positive effect on the survival times (P < 0.01). Relapsed small cell lung cancer still shows a response to second-line chemotherapy without lessening survival time, and thus clinical trials of new drugs or combination chemotherapeutic regimens for relapsed small cell lung cancer cases would be reasonably justified. Randomized comparative studies are warranted for determining the benefits of second-line chemotherapy for relapsed small cell lung cancer cases.
Collapse
Affiliation(s)
- N Ebi
- Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Kakinuma R, Imatsu H, Kaneko M, Eguchi K. [Lung cancer: progress in diagnosis and treatment. I. Diagnosis and physiopathology: 2. On the lung screening system--cytodiagnosis and CT examination]. Nihon Naika Gakkai Zasshi 1997; 86:10-4. [PMID: 9102407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
45
|
Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Yamamoto N, Kurata T, Kasai T, Ohmatsu H, Kubota K, Sekine I, Hojo N, Matsumoto T, Kodama T, Kakinuma R, Nishiwaki Y, Saijo N. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br J Cancer 1997; 76:1494-9. [PMID: 9400948 PMCID: PMC2228187 DOI: 10.1038/bjc.1997.584] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
We conducted a phase I study of irinotecan (CPT-11) and etoposide (VP-16) given sequentially to untreated patients with metastatic non-small-cell lung cancer. Arm A: CPT-11 was given over 90 min on days 1-3 and VP-16 was given over 60 min on days 4-6. Arm B: VP-16 was given on days 1-3 and CPT-11 on days 4-6. G-CSF was given to all patients daily on days 7-17. Twenty-seven patients were entered randomly at the two arms. The major dose-limiting toxicities in arms A and B were granulocytopenia and diarrhoea. Transient elevations of transaminases and bilirubin were observed in both arms. The degree of the toxicities did not differ between the two arms. The maximum tolerated doses (MTDs) were 60 mg m-2 CPT-11 and 60 mg m-2 VP-16 in both arms. Of the 13 patients who received more than two cycles, two out of five achieved partial response (PR) at the first level of arm A and one out of four achieved PR at the second level of arm B. We conclude that these schedules of sequential CPT-11 and VP-16 administration were inappropriate because of severe toxicities.
Collapse
Affiliation(s)
- M Ando
- The Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Kubota K, Nishiwaki Y, Kakinuma R, Hojo F, Matsumoto T, Ohmatsu H, Sekine I, Yokozaki M, Goto K, Ebi N, Kodama T. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 1997; 15:292-6. [PMID: 8996155 DOI: 10.1200/jco.1997.15.1.292] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE This study was undertaken to determine the activity and toxicity of dose-intensive weekly chemotherapy (cisplatin, vincristine, doxorubicin, and etoposide [CODE] regimen) for previous treated, recurrent small-cell lung cancer (SCLC). PATIENTS AND METHODS The 17 patients with relapsed SCLC entered onto the study were to receive intensive weekly chemotherapy with the CODE regimen. All 17 patients had been heavily pretreated with some form of cisplatin-based combination chemotherapy. Six patients had received previous chemotherapy with CODE and one patient with cisplatin and etoposide (PE) as induction therapy. Nine patients had been treated with concurrent or sequential PE plus thoracic irradiation (TRT). The median time off chemotherapy was 6.7 months (range, 3.3 to 72). Patients were treated with 9 weeks of the CODE regimen. Response, survival, and toxicity data were noted. RESULTS All 17 patients were assessable for response, survival, and toxicity. Fifteen of 17 patients (88.2%) had an objective response, with five complete responses (CRs; 29%) and 10 partial responses (PRs; 58.8%). The median durations of response and survival were 156 days and 245 days, respectively. Myelosuppression was significant, with 76% of patients developing grade 4 leukopenia. No treatment-related death was observed. CONCLUSION The CODE regimen is highly active in the treatment of relapsed SCLC with an encouraging survival outcome.
Collapse
Affiliation(s)
- K Kubota
- Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Yokozaki M, Goto K, Miyamoto T, Takafuji J, Kodama T. Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413. Br J Cancer 1997; 76:90-2. [PMID: 9218738 PMCID: PMC2223781 DOI: 10.1038/bjc.1997.341] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Thirty-three patients with lung cancer receiving 80 mg m(-2) cisplatin were treated with high-dose dexamethasone (32 mg m(-2) on days 1-3, 16 mg m(-2) on day 4 and 8 mg m(-2) on day 5) combined with granisetron on day 1 and metoclopramide on days 2-5. Twenty-eight (85%) patients had no nausea or vomiting on day 1, and 16 (48%) achieved total control on days 1-5 with acceptable toxicity. High-dose dexamethasone for cisplatin-induced delayed emesis should be further evaluated in a phase III trial.
Collapse
Affiliation(s)
- I Sekine
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa-city, Chiba, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K, Moriyama N. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996; 201:798-802. [PMID: 8939234 DOI: 10.1148/radiology.201.3.8939234] [Citation(s) in RCA: 644] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
PURPOSE To compare low-dose spiral computed tomography (CT) with radiography of the chest for the screening and detection of small peripheral lung cancers in a high-risk population. MATERIALS AND METHODS Posteroanterior and lateral radiographs and low-dose spiral CT scans were obtained twice a year from September 1993 to April 1995 in 1,369 individuals (a total of 3,457 examinations) who were at high risk for lung cancer. Low-dose spiral CT parameters were 120 kvP, 50 mA, 10-mm collimation, and 2:1 pitch. RESULTS Peripheral lung cancer was detected in 15 of 3,457 examinations (0.3%). Among the 15 cases, the results of chest radiography were negative in 11 (73%), and the tumors were detected only at low-dose spiral CT. The detection rates of low-dose spiral CT and chest radiography were 0.43% (15 of 3,457 examinations), respectively. Fourteen (93%) of the 15 (exclusion of one pulmonary lung cancer) tumors were stage I. CONCLUSION Low-dose spiral CT was superior to chest radiography in the screening and detection of peripheral lung cancer in high-risk individuals. Further large-scale studies are warranted, however, to clarify the efficacy and cost-effectiveness of low-dose spiral CT in a randomized, controlled population.
Collapse
Affiliation(s)
- M Kaneko
- Division of Endoscopy, National Cancer Center Hospital, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
49
|
Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Yokozaki M, Goto K, Kodama T. Late recurrence of small-cell lung cancer: treatment and outcome. Oncology 1996; 53:318-21. [PMID: 8692537 DOI: 10.1159/000227580] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The 2-year survival of patients with small-cell lung cancer (SCLC) with limited disease is about 25% and the survival curve continues to decline after 2 years. We reviewed 34 cases of survivors of SCLC who had been free of disease for 2 years and who constituted 12.2% of the 278 patients with SCLC newly diagnosed at our institution from 1977 to 1991. The cancer had recurred in 13 patients, 10 of whom were treated with chemotherapy and/or radiotherapy, and 1 complete and 1 partial response were obtained. Three patients received only supportive care because of poor performance status. The median survival after recurrence in the 13 patients was 7.4 months (range 0-39 months). A second primary cancer was noted in 5 patients, but 3 of them died from recurrence of SCLC. The prognosis of patients with late recurrence of SCLC was relatively good, and it seems that adequate treatment in such cases may lead to long-term survival.
Collapse
Affiliation(s)
- I Sekine
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Yokozaki M, Kodama T. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis. Jpn J Clin Oncol 1996; 26:164-8. [PMID: 8656557 DOI: 10.1093/oxfordjournals.jjco.a023201] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
We studied the role of dexamethasone (DEX) administered on day 1 in controlling cisplatin-induced delayed emesis. Forty patients were randomly allocated to receive either granisetron (GRN) and DEX on day 1, or the same dose of GRN alone. On days 2-5, all the patients received metoclopramide and DEX. They were crossed over to the other antiemetic regimen with their second course of chemotherapy. Thirty-one patients were evaluable for efficacy. The mean visual analogue scale scores for nausea on days 1 and 2 were 9.1 and 18.8 mm for GRN and DEX, and 16.3 and 28.5 mm for GRN alone, respectively (P<0.05 on day 2). The mean numbers of emetic episodes on days 1-3 were 0.036, 0.46 and 0.36 for GRN and DEX, and 0.39, 0.89 and 0.57 for GRN alone, respectively (P<0.01 on day 1). Hiccups and restlessness were noted in 38% and 33% of cycles, respectively. Addition of DEX to GRN on day 1 thus enhanced the control of delayed emesis.
Collapse
Affiliation(s)
- I Sekine
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|